A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group,
three-arm, multicenter study of the safety and PK of ELND005 administered orally for 4 weeks.
This study will enroll Down Syndrome patients 18 to 45 years of age (inclusive) without
dementia.
Phase:
Phase 2
Details
Lead Sponsor:
OPKO Health, Inc. Transition Therapeutics Ireland Limited